Author Archives: Patricia Inacio PhD

Nonprofits Working to Add PWS to Newborn Screening in North Carolina

Four organizations have joined efforts to fund the addition of Prader-Willi syndrome, Angelman syndrome, and Dup15q syndrome to the Early Check newborn screening panel in North Carolina. The initiative is led by the Foundation for Prader-Willi Research (FPWR), Angelman Syndrome Foundation, Foundation for Angelman Syndrome Therapeutics (FAST), and…

Dosing Begins in Phase 1 Trial of INV-102, Potential PWS Therapy

The first healthy volunteers were dosed in a Phase 1 clinical trial evaluating Inversago Pharma‘s INV-102, a potential therapy for Prader-Willi syndrome (PWS) and other metabolic disorders. According to a company press release, the trial, underway in Canada, started dosing following a “No Objection Letter” from Health Canada.

First PWS Genome Sequencing Project Now Enrolling Participants

The Foundation for Prader-Willi Research (FPWR) is launching the first Prader-Willi syndrome (PWS) Genome Project, it announced. This project aims to unveil how variations in patients’ DNA influence the range and severity of PWS symptoms, and impacts response to different treatments. Initially, it is looking to enroll about…